Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 1, 2012, Pages

  Braun, Doreen ^a   Kim, Theo D ^a   Le Coutre, Philipp ^a   Köhrle, Josef ^a   Hershman, Jerome M ^b   Schweizer, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; IODOTHYRONINE; MONOCARBOXYLATE TRANSPORTER 8; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG STRUCTURE; EFFUSION; GENE; GENE MUTATION; HORMONE INHIBITION; HORMONE TRANSPORT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MCT8 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID FUNCTION TEST;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; DOGS; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; IODINE RADIOISOTOPES; MONOCARBOXYLIC ACID TRANSPORTERS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; THYROXINE; TRANSFECTION; TRIIODOTHYRONINE;

EID: 84862956363     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1837     Document Type: Article

References (25)

1. Arora A, Scholar EM 2005 Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971-979
2. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
3. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83
4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664
5. Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ 2007 Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:974-975; author reply 976-977
6. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534
7. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454
8. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355
9. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149
10. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP 2005 Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438
11. Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, Maia AL 2008 Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 158:771-772
12. Salem AK, Fenton MS, Marion KM, Hershman JM 2008 Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-635
13. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ 2011 Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 96:3087-3094
14. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, Braun D, Schweizer U, Arnold R, Dörken B, le Coutre P 2010 Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20:1209-1214
15. Kinne A, Roth S, Biebermann H, Köhrle J, Grüters A, Schweizer U 2009 Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type-dependent. J Mol Endocrinol 43:263-271
16. Roth S, Kinne A, Schweizer U 2010 The tricyclic antidepressant desipramine inhibits T3 import into primary neurons. Neurosci Lett 478:5-8
17. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E, Romijn JA, Visser TJ, Smit JW 2010 Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 95:3758-3762
18. Bauer M, Hellweg R, Gräf KJ, Baumgartner A 1998 Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18:444-455
19. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, Wang DN 2007 LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317:1390-1393
20. Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, Grindstaff KK, Mengesha W, Raman C, Zerangue N 2008 Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology 149:6251-6261
21. 3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci 29:9439-9449
22. Braun D, Kinne A, Bräuer AU, Sapin R, Klein MO, Köhrle J, Wirth EK, Schweizer U 2011 Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia 59:463-471
23. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
24. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
25. Brassard M, Neraud B, Trabado S, Salenave S, Brailly-Tabard S, Borget I, Baudin E, Leboulleux S, Chanson P, Schlumberger M, Young J 2011 Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab 96:2741-2749